Anti-Obesity Drug Linked To 5 Deaths In U.K.

Law360, New York (June 3, 2008, 12:00 AM EDT) -- Acomplia, the Sanofi-Aventis SA anti-obesity drug rejected by the U.S. Food and Drug Administration last year due to fears of psychiatric side effects, has been linked to five deaths, including one suicide, since it went on sale in the United Kingdom in 2006, new data show.

According to a report posted Tuesday on the Web site of the Medicines and Healthcare Products Regulatory Agency, the FDA's U.K. counterpart, 720 people in the U.K. reported adverse drug reactions from use of rimonabant, marketed in the U.K. as...
To view the full article, register now.